• Something wrong with this record ?

Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria

BP. Rai, J. Luis Dominguez Escrig, L. Vale, T. Kuusk, O. Capoun, V. Soukup, HM. Bruins, Y. Yuan, PD. Violette, N. Santesso, BWG. van Rhijn, A. Hugh Mostafid, M. Imran Omar

. 2022 ; 82 (2) : 182-192. [pub] 20220405

Language English Country Switzerland

Document type Journal Article, Review, Systematic Review

Persistent link   https://www.medvik.cz/link/bmc22025017

CONTEXT: The current impact of haematuria investigations on health care organisations is significant. There is currently no consensus on how to investigate patients with haematuria. OBJECTIVE: To evaluate the incidence of bladder cancer, upper tract urothelial carcinoma (UTUC), and renal cell carcinoma (RCC) among patients undergoing investigation for haematuria and identify any risk factors for bladder cancer, UTUC, and RCC (BUR). EVIDENCE ACQUISITION: Medline, Embase, and Cochrane controlled trials databases and ClinicalTrials.gov were searched for all relevant publications from January 1, 2000 to June 2021 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Prospective, retrospective, and cross-sectional studies with a minimum population of 50 patients with haematuria were considered for the review. EVIDENCE SYNTHESIS: A total of 44 studies were included. The total number of participants was 229701. The pooled incidence rate for urothelial bladder cancer was 17% (95% confidence interval [CI] 14-20%) for visible haematuria (VH) and 3.3% (95% CI 2.45-4.3%) for nonvisible haematuria (NVH). The pooled incidence rate for RCC was 2% (95% CI 1-2%) for VH and 0.58% (95% CI 0.42-0.77%) for NVH. The pooled incidence rate for UTUC was 0.75% (95% CI 0.4-1.2%) for VH and 0.17% (95% CI 0.081-0.299%) for NVH. On sensitivity analysis, the proportions of males (risk ratio [RR] 1.14, 95% CI 1.10-1.17 for VH; 1.54, 95% CI 1.34-1.78 for NVH; p < 0.00001; moderate certainty evidence) and individuals with a smoking history (RR 1.41, 95% CI 1.24-1.61 for VH; 1.53, 95% CI 1.36-1.72 for NVH; p < 0.00001; moderate certainty evidence) appeared to be higher in BUR than in non-BUR groups. CONCLUSIONS: Male gender and smoking history are risk factors for BUR cancer in haematuria, with bladder cancer being the commonest cancer. The incidence of RCC and UTUC in NVH is low. The review serves as a reference standard for future policy-making on investigation of haematuria by global organisations. PATIENT SUMMARY: Our review shows that male gender and smoking history are risk factors for cancers of the bladder, kidney, and ureter. The review also provides information on the proportion of patients who have cancer when they have blood in their urine (haematuria) and will allow policy-makers to decide on the most appropriate method for investigating haematuria in patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025017
003      
CZ-PrNML
005      
20221031100509.0
007      
ta
008      
221017s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2022.03.027 $2 doi
035    __
$a (PubMed)35393159
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rai, Bhavan P $u Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: urobhavan@gmail.com
245    10
$a Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria / $c BP. Rai, J. Luis Dominguez Escrig, L. Vale, T. Kuusk, O. Capoun, V. Soukup, HM. Bruins, Y. Yuan, PD. Violette, N. Santesso, BWG. van Rhijn, A. Hugh Mostafid, M. Imran Omar
520    9_
$a CONTEXT: The current impact of haematuria investigations on health care organisations is significant. There is currently no consensus on how to investigate patients with haematuria. OBJECTIVE: To evaluate the incidence of bladder cancer, upper tract urothelial carcinoma (UTUC), and renal cell carcinoma (RCC) among patients undergoing investigation for haematuria and identify any risk factors for bladder cancer, UTUC, and RCC (BUR). EVIDENCE ACQUISITION: Medline, Embase, and Cochrane controlled trials databases and ClinicalTrials.gov were searched for all relevant publications from January 1, 2000 to June 2021 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Prospective, retrospective, and cross-sectional studies with a minimum population of 50 patients with haematuria were considered for the review. EVIDENCE SYNTHESIS: A total of 44 studies were included. The total number of participants was 229701. The pooled incidence rate for urothelial bladder cancer was 17% (95% confidence interval [CI] 14-20%) for visible haematuria (VH) and 3.3% (95% CI 2.45-4.3%) for nonvisible haematuria (NVH). The pooled incidence rate for RCC was 2% (95% CI 1-2%) for VH and 0.58% (95% CI 0.42-0.77%) for NVH. The pooled incidence rate for UTUC was 0.75% (95% CI 0.4-1.2%) for VH and 0.17% (95% CI 0.081-0.299%) for NVH. On sensitivity analysis, the proportions of males (risk ratio [RR] 1.14, 95% CI 1.10-1.17 for VH; 1.54, 95% CI 1.34-1.78 for NVH; p < 0.00001; moderate certainty evidence) and individuals with a smoking history (RR 1.41, 95% CI 1.24-1.61 for VH; 1.53, 95% CI 1.36-1.72 for NVH; p < 0.00001; moderate certainty evidence) appeared to be higher in BUR than in non-BUR groups. CONCLUSIONS: Male gender and smoking history are risk factors for BUR cancer in haematuria, with bladder cancer being the commonest cancer. The incidence of RCC and UTUC in NVH is low. The review serves as a reference standard for future policy-making on investigation of haematuria by global organisations. PATIENT SUMMARY: Our review shows that male gender and smoking history are risk factors for cancers of the bladder, kidney, and ureter. The review also provides information on the proportion of patients who have cancer when they have blood in their urine (haematuria) and will allow policy-makers to decide on the most appropriate method for investigating haematuria in patients.
650    12
$a karcinom z renálních buněk $x komplikace $x epidemiologie $7 D002292
650    12
$a karcinom z přechodných buněk $x komplikace $x epidemiologie $7 D002295
650    _2
$a průřezové studie $7 D003430
650    _2
$a hematurie $x epidemiologie $x etiologie $7 D006417
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    12
$a nádory ledvin $x komplikace $x epidemiologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    12
$a nádory močového měchýře $x komplikace $x epidemiologie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Luis Dominguez Escrig, José $u Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
700    1_
$a Vale, Luís $u Department of Urology, Centro Hospital Universitário S. João, Porto, University of Porto, Porto, Portugal
700    1_
$a Kuusk, Teele $u Department of Urology, Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford, UK
700    1_
$a Capoun, Otakar $u Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Soukup, Viktor $u Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Bruins, Harman M $u Department of Urology, Zuyderland Medical Center, Sittard-Geleen-Heerlen, The Netherlands
700    1_
$a Yuan, Yuhong $u Department of Medicine, Health Science Centre, McMaster University, Hamilton, ON, Canada
700    1_
$a Violette, Philippe D $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada
700    1_
$a Santesso, Nancy $u Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Michael G. DeGroote Cochrane Canada Centre, McMaster University, Hamilton, ON, Canada
700    1_
$a van Rhijn, Bas W G $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
700    1_
$a Hugh Mostafid, A $u Department of Urology, Royal Surrey County Hospital, Guildford, UK
700    1_
$a Imran Omar, Muhammad $u Academic Urology Unit, University of Aberdeen, Aberdeen, UK
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 82, č. 2 (2022), s. 182-192
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35393159 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100507 $b ABA008
999    __
$a ok $b bmc $g 1854626 $s 1176307
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 82 $c 2 $d 182-192 $e 20220405 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options